Search results for "antipsychotic"

showing 10 items of 189 documents

Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclo…

2008

To elucidate the Batypicality( of ziprasidone, its striatal and extrastriatal D2/D3-receptor binding was characterized in patients with schizophrenia under steady-state conditions. These data were compared with striatal receptor occupancy values after single-dose ziprasidone ingestion in healthy controls. ( 18 F)fallypride positron emission tomography (PET) recordings were obtained in 15 patients under steady-state ziprasidone treatment at varying time points after the last dose. Binding potentials were calculated for striatal and extrastriatal regions. D2/D3-receptor occupancies were expressed relative to binding potentials in 8 unmedicated patients. In a parallel ( 11 C)raclopride-PET stu…

AdultMalemedicine.medical_specialtyFluorine RadioisotopesPyrrolidinesTime Factorsmedicine.drug_classAtypical antipsychoticPharmacologyBinding CompetitiveBasal GangliaPiperazinesYoung AdultDopamine receptor D3Internal medicinemedicineHaloperidolHumansPharmacology (medical)ZiprasidoneCarbon RadioisotopesTemporal cortexRacloprideDose-Response Relationship DrugChemistryReceptors Dopamine D2Dopamine antagonistReceptors Dopamine D3Psychiatry and Mental healthThiazolesEndocrinologyFallyprideRaclopridePositron-Emission TomographyBenzamidesSchizophreniaDopamine AntagonistsFemaleRadiopharmaceuticalsmedicine.drugAntipsychotic AgentsJournal of clinical psychopharmacology
researchProduct

Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders : Valid predictors of symptomatic response and remiss…

2010

To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome.Biweekly PANSS ratings were performed in 285 inpatients with schizophrenia spectrum disorders within a multicenter trial by the German Research Network on Schizophrenia. Quality of life and subjective well-being were assessed using the Medical Outcomes Study-Short Form 36-Item Health Survey (SF-36), the Subjective Well-being Under Neuroleptic Treatment Scale (SWN-K) and the Adjective Mood Scale (AMS). Response was defined as an initial 20% PANSS total score reduction and remission according to the consensus criteria. Correlation analysis, logistic regression and CART-analysis were performed.I…

AdultMalemedicine.medical_specialtyMedizinLogistic regressionMood scale03 medical and health sciencesYoung Adult0302 clinical medicineQuality of lifeMulticenter trialInternal medicinemedicineHumansSubjective well-beingBiological PsychiatryPsychiatric Status Rating ScalesMiddle Agedmedicine.diseasePrognosisAntidepressive Agents3. Good health030227 psychiatryHospitalizationPsychiatry and Mental healthTranquilizing AgentsPsychotic DisordersSchizophreniaCorrelation analysisQuality of LifeSchizophreniaDrug Therapy CombinationFemaleSchizophrenic PsychologyPsychology030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyAntipsychotic Agents
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response

2008

The aim of the present study was to examine the relevance of depressive symptoms during an acute schizophrenic episode for the prediction of treatment response. Two hundred inpatients who fulfilled DSM-IV criteria for schizophrenia or schizophreniform disorders were assessed at hospital admission and after 6 weeks of inpatient treatment using the Positive and Negative Syndrome Scale (PANSS) and the Hamilton Rating Scale for Depression (HAM-D). Depressive symptoms showed positive correlations with both positive and negative symptoms at admission and after 6 weeks, and decreased during 6 weeks of treatment. Pronounced depressive symptoms (HAM-D score> or =16) were found in 28% of the sample a…

AdultMalemedicine.medical_specialtyPsychosis610 Medicine & healthComorbidity10056 Clinic for Clinical and Social Psychiatry Zurich West (former)law.invention2738 Psychiatry and Mental Health03 medical and health sciencesPatient Admission0302 clinical medicineRandomized controlled triallawInternal medicinemental disordersmedicineHumansSchizophreniform disorderPsychiatryBiological PsychiatryDepression (differential diagnoses)ProbabilityPsychiatric Status Rating ScalesDepressive DisorderDepressive Disorder MajorPsychotropic DrugsPositive and Negative Syndrome ScaleHamilton Rating Scale for Depressionmedicine.diseaseComorbidity030227 psychiatryDiagnostic and Statistical Manual of Mental DisordersHospitalizationPsychiatry and Mental healthTreatment OutcomePsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychology2803 Biological Psychiatry030217 neurology & neurosurgeryAntipsychotic AgentsFollow-Up Studies
researchProduct

Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia

2006

This clinical study analyzed gender-specific relationships of depression with other psychopathological and clinical variables in hospitalized patients with schizophrenia. During clinical routine treatment 119 inpatients with acute schizophrenia (DSM-IV) were investigated with the Calgary Depression Rating Scale for Schizophrenia (CDSS), the Clinical Global Impressions (CGI), and the Positive and Negative Syndrome Scale (PANSS). Depression scores of 77 male and 42 female patients (mean age 31.6+/-10.3 years) were related to background variables and to positive and negative symptom scores. Mean CDSS (5.8+/-5.6) and PANSS scores (total 76.9+/-22.1, positive symptoms 17.6+/-7.6, negative sympto…

AdultMalemedicine.medical_specialtyPsychosisAdolescentAcute schizophreniaRating scaleInternal medicinemental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesPharmacologySex CharacteristicsPositive and Negative Syndrome ScaleDepressionLength of StayMiddle Agedmedicine.diseaseAntidepressive AgentsHospitalizationSchizophreniaAcute DiseaseSchizophreniaRegression AnalysisFemaleSchizophrenic PsychologyPsychologyAntipsychotic AgentsPsychopathologyClinical psychologySex characteristicsProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Pseudoneglect in schizophrenia: A line bisection study with cueing

2007

Numerous authors have reported the existence of lateralised abnormalities towards the right side in patients with schizophrenia.In the present study, a manual line bisection task was used to assess the existence of a visuospatial bias in patients with schizophrenia as compared to healthy subjects and left unilateral neglect patients. In addition, we used a local cueing paradigm (consisting of a number placed on the right, on the left, or at both ends of the line).Healthy subjects showed a leftwards trend in the "no cue" condition (known as pseudoneglect) and neglect patients showed a right bias in all cue conditions. In contrast, patients with schizophrenia placed their manual estimation of…

AdultMalemedicine.medical_specialtyPsychosisCognitive Neurosciencemedia_common.quotation_subjectSchizophrenia (object-oriented programming)AudiologyNeglectPerceptual DisordersmedicineHumansIn patientmedia_commonHealthy subjectsSpace perceptionCognitionMiddle Agedmedicine.diseasePsychiatry and Mental healthUnilateral neglectSpace PerceptionSchizophreniaVisual PerceptionFemaleCuesVisual FieldsPsychologyAntipsychotic AgentsCognitive psychologyCognitive Neuropsychiatry
researchProduct

Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis.

2013

This randomized open-label study compared the incidence of metabolic side effects of aripiprazole, ziprasidone and quetiapine in a population of medication-naive first-episode psychosis patients. A total of 202 subjects were enrolled. Body weight, body mass index, leptin, fasting lipids and fasting glycaemic parameters were measured at baseline and at 3 months follow-up. A hundred and sixty-six patients completed the follow-up and were included in the analyses. A high proportion of patients experienced a significant weight increase (>7% of their baseline weight): 23% ziprasidone (n=12), 32% with quetiapine (n=16) and 45% with aripiprazole (n=31). Patients treated with aripiprazole gained si…

AdultMalemedicine.medical_specialtyPsychosisDibenzothiazepinesPopulationAripiprazoleQuinolonesWeight GainGastroenterologyPiperazinesQuetiapine FumarateSex FactorsInternal medicinemedicineHumansZiprasidoneeducationPsychiatryBiological Psychiatryeducation.field_of_studybusiness.industryLeptinmedicine.diseaseProlactinPsychiatry and Mental healthThiazolesCholesterolPsychotic DisordersQuetiapineAripiprazoleFemalemedicine.symptombusinessWeight gainBody mass indexmedicine.drugAntipsychotic AgentsFollow-Up StudiesSchizophrenia research
researchProduct

Metabolic Syndrome and Cardiovascular Risk in People Treated with Long-Acting Injectable Antipsychotics

2017

BACKGROUND People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics. METHODS This is a cross-sectional study developed in an outpatient mental health clinic in which the preva…

AdultMalemedicine.medical_specialtyPsychosisHealth StatusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentHealth BehaviorDiseasePharmacologyRisk AssessmentSeverity of Illness IndexInjectionsHabitsYoung Adult03 medical and health sciences0302 clinical medicineCost of IllnessRisk FactorsInternal medicinePrevalencemedicineHumansImmunology and AllergyAntipsychoticLife StyleAgedMetabolic SyndromeFramingham Risk Scorebusiness.industryMental DisordersMiddle Agedmedicine.diseaseMental healthObesity030227 psychiatryCross-Sectional StudiesCardiovascular DiseasesSpainSchizophreniaDelayed-Action PreparationsFemaleMetabolic syndromebusiness030217 neurology & neurosurgeryAntipsychotic AgentsEndocrine, Metabolic & Immune Disorders - Drug Targets
researchProduct

Outcome of suicidal patients with schizophrenia: results from a naturalistic study.

2010

Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller H-J, Riedel M. Outcome of suicidal patients with schizophrenia: results from a naturalistic study. Objective:  Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences. Method:  Biweekly PANSS (Positive and Negative Syndrome Scale), HAMD (Hamilton Depression Rating Scale) and UKU (Udvalg for Klinske Undersogelser Side Effect Rating Scale) ratings were evaluated in 339 in-patients with schizophrenic spectrum disorder…

AdultMalemedicine.medical_specialtyPsychosisMedizinPoison controlSuicide AttemptedComorbidityAkathisiaCohort StudiesHospitals University03 medical and health sciencesYoung Adult0302 clinical medicineRating scaleRisk FactorsGermanyHamdmedicineHumansPsychiatryPsychiatric Status Rating ScalesDepressive Disorder MajorPositive and Negative Syndrome ScaleIncidenceMiddle Agedmedicine.diseaseComorbidityHealth Surveys3. Good health030227 psychiatryPsychiatry and Mental healthCross-Sectional StudiesTreatment OutcomeSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychology030217 neurology & neurosurgeryAkathisia Drug-InducedAntipsychotic AgentsActa psychiatrica Scandinavica
researchProduct

The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia.

2005

Positron emission tomography (PET) studies reveal that clozapine at clinically used doses occupies less than 60% of D2/D3 dopamine receptors in human striatum. Here, the occupancy of D2/D3 dopamine receptors by clozapine in patients with schizophrenia was determined to test the hypothesis that clozapine binds preferentially to extrastriatal dopamine receptors. A total of 15 clozapine-treated inpatients with schizophrenia underwent a [18F]fallypride PET scan. Receptor occupancy was calculated as percent reduction in binding potential relative to unblocked values measured in seven normal volunteers. Mean D2/D3 receptor occupancy was statistically significantly higher in cortical (inferior tem…

AdultMalemedicine.medical_specialtyPsychosisPyrrolidinesDopamineStriatumBinding CompetitiveReceptors DopamineDopamine receptor D3Internal medicinemedicineHumansClozapineClozapinePharmacologyTemporal cortexDose-Response Relationship DrugChemistryReceptors Dopamine D2PutamenReceptors Dopamine D3Middle Agedmedicine.diseaseCorpus StriatumTemporal LobePsychiatry and Mental healthEndocrinologyFallyprideDopamine receptorAnesthesiaPositron-Emission TomographyBenzamidesSchizophreniaFemalemedicine.drugAntipsychotic AgentsNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct